1e
19
1
49
2
2
18
1b
1d
18
34
63
1d
2 29
1d
25
Robert B. Norris, M.D.
78
63
Clinical Associate Professor of Medicine (Medicine Affiliates)
28
73
3
5f
Attending Physician, Pennsylvania Hospital, Philadelphia, PA
65
Penn Medicine Clinician, Pennsylvania Hospital
a5
Director , Cardiology Outpatient Practice Operations, Penn Heart and Vascular Center at Pennsylvania Hospital
11
Department: Medicine
4
1
b
1d
46
Contact information
65
4
3
3
3
2
4
b
1f
65
Penn Heart and Vascular Center at Pennsylvania Hospital
2b Farm Journal Building, Third Floor,
3d 230 West Washington Square
Philadelphia, PA 19106
26
2b Farm Journal Building, Third Floor,
3d 230 West Washington Square
Philadelphia, PA 19106
2e
Office: 215-829-5064
30
a9
12
30
13
Education:
21 9 B.A. 14 (Biology) c
33 University of Pennsylvania, 1980.
21 9 B.S. 1b (Wharton School) c
33 University of Pennsylvania, 1980.
21 9 M.D. 14 (Science) c
3b New York University Medical School, 1984.
c
3
3
3
3
8a
Permanent link21 9 B.A. 14 (Biology) c
33 University of Pennsylvania, 1980.
21 9 B.S. 1b (Wharton School) c
33 University of Pennsylvania, 1980.
21 9 M.D. 14 (Science) c
3b New York University Medical School, 1984.
c
2 29
21
1e
1d
24
5e
8
a1 CRISP: A single arm open label study of a statin in community-based patients with cardiovascular disease. Mayo Alliance for Clinical Trials. (2000-2001)
8
13c AIM-HIGH: Trial examining the safety and effectiveness of a combination regimen of extended release niacin and simvastatin vs simvastatin alone for prevention of cardiovascular events in patients with cardiovascular disease and low HDL/high triglycerides. NIH sponsored. (2006-present; study stopped in 2011)
8
128 DAL-OUTCOMES: Multi-centered trial evaluating the efficacy, safety and clinical outcomes of treatment with dalcetrapib, a CETP modulating agent which raises HDL, in the treatment of who have experienced an acute coronary syndrome. Industry sponsored. (2009-present; recruitment complete)
8
10c ALECARDIO: Multi-centered trial evaluating cardiovascular outcomes of treatment with aleglitizar, a dual PPAR inhibitor, in the treatment of diabetics who have experienced an acute coronary syndrome. Industry sponsored. (2010-present; recruitment in progress)
65
62
e 7 1d 1f
27
Description of Research Expertise
66 Investigator, Multicenter Trials in the Management of Lipids and Cardiovascular Risk:8
a1 CRISP: A single arm open label study of a statin in community-based patients with cardiovascular disease. Mayo Alliance for Clinical Trials. (2000-2001)
8
13c AIM-HIGH: Trial examining the safety and effectiveness of a combination regimen of extended release niacin and simvastatin vs simvastatin alone for prevention of cardiovascular events in patients with cardiovascular disease and low HDL/high triglycerides. NIH sponsored. (2006-present; study stopped in 2011)
8
128 DAL-OUTCOMES: Multi-centered trial evaluating the efficacy, safety and clinical outcomes of treatment with dalcetrapib, a CETP modulating agent which raises HDL, in the treatment of who have experienced an acute coronary syndrome. Industry sponsored. (2009-present; recruitment complete)
8
10c ALECARDIO: Multi-centered trial evaluating cardiovascular outcomes of treatment with aleglitizar, a dual PPAR inhibitor, in the treatment of diabetics who have experienced an acute coronary syndrome. Industry sponsored. (2010-present; recruitment in progress)
65
Description of Clinical Expertise
d7 Organized and performed non-invasive cardiovascular evaluation (EKG and ECHO) of the 2010 Men's World Cup Soccer Team, as directed by Fédération Internationale de Football Association (FIFA). 201062
Description of Other Expertise
a5 Operation Walk: Worked in Panama with this volunteer medical service organization which performs surgery in under-developed countries. November 2009.e 7 1d 1f